CenterBook Partners LP Has $2.56 Million Holdings in Bio-Rad Laboratories, Inc. $BIO

CenterBook Partners LP trimmed its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 36.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,129 shares of the medical research company’s stock after selling 5,224 shares during the period. CenterBook Partners LP’s holdings in Bio-Rad Laboratories were worth $2,560,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in BIO. Royal Bank of Canada boosted its stake in Bio-Rad Laboratories by 25.2% during the first quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company’s stock worth $7,382,000 after buying an additional 6,100 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Bio-Rad Laboratories by 45.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company’s stock valued at $25,575,000 after acquiring an additional 32,874 shares in the last quarter. Empowered Funds LLC increased its stake in Bio-Rad Laboratories by 14.8% in the first quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company’s stock valued at $377,000 after acquiring an additional 199 shares during the period. Jane Street Group LLC raised its position in Bio-Rad Laboratories by 95.3% in the first quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company’s stock worth $9,105,000 after purchasing an additional 18,239 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Bio-Rad Laboratories in the second quarter worth about $652,000. Institutional investors own 65.24% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on BIO shares. Citigroup lifted their price objective on Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 29th. Wall Street Zen lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Wells Fargo & Company boosted their target price on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of “Hold” and a consensus target price of $358.50.

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock opened at $271.79 on Friday. Bio-Rad Laboratories, Inc. has a 12-month low of $211.43 and a 12-month high of $343.12. The stock has a 50-day simple moving average of $301.86 and a 200 day simple moving average of $301.07. The company has a quick ratio of 4.19, a current ratio of 5.62 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $7.33 billion, a price-to-earnings ratio of 9.74 and a beta of 1.18.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, February 12th. The medical research company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $2.57 by ($0.06). The company had revenue of $693.20 million during the quarter, compared to the consensus estimate of $694.64 million. Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.The business’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter last year, the firm earned $2.90 EPS. On average, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.